# Supernus Pharmaceuticals

Type: Company (SUPN)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/supernus-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/supernus-pharmaceuticals

## Recent coverage (2 stories)

### NovoCure and Supernus Signal Growth in Q4 2025 Earnings Amid Product Expansions
2026-02-26 22:39:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 7

NovoCure and Supernus Pharmaceuticals reported Q4 2025 results, highlighting a pivotal year for commercial expansion in oncology and CNS markets. Both companies are navigating the transition from R&D-heavy phases to sustained commercial growth following key regulatory milestones.
Full story: https://getbiobrief.com/story/novocure-supernus-q4-2025-earnings-analysis

### Pharma Earnings Preview: Supernus and Corcept Set for Q4 2025 Results
2026-02-23 22:52:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Supernus Pharmaceuticals and Corcept Therapeutics are preparing to report Q4 2025 results, with investors focusing on CNS product growth and cortisol-modulating pipeline progress. These reports will provide critical data on market penetration for key therapies like Qelbree and Korlym amidst a shifting regulatory landscape.
Full story: https://getbiobrief.com/story/supernus-corcept-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.